VAG
HAE icon

VisionPoint Advisory Group’s Haemonetics HAE Stock Holding History

VisionPoint Advisory Group’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3
Closed -$248 – 463
2024
Q2 		$248 Hold
3
– – ﹤0.01% 759
2024
Q1 		$256 Buy
+3
New +$235 ﹤0.01% 763

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

VisionPoint Advisory Group's HAE Position: Q3 2024 in Review

VisionPoint Advisory Group sold out of Haemonetics (HAE) in Q3 2024, closing a stake of 3 shares — an estimated $248 sold.

VisionPoint Advisory Group first reported a position in HAE in Q1 2024 and held it in 2 quarters. The position peaked at $256 in Q1 2024. 306 funds tracked by Wall St. Rank hold HAE as of Q3 2024.

  • VisionPoint Advisory Group reported no remaining Haemonetics position as of Q3 2024 after selling out during the quarter.
  • VisionPoint Advisory Group sold 3 Haemonetics shares in Q3 2024, an estimated $248.
  • VisionPoint Advisory Group first reported a position in Haemonetics in Q1 2024 and held it in 2 quarters.
  • VisionPoint Advisory Group's Haemonetics position peaked at $256 in Q1 2024.
  • 306 funds tracked by Wall St. Rank held Haemonetics as of Q3 2024.

Based on VisionPoint Advisory Group's 13F filing for Q3 2024, filed 15 Oct 2024.